Assenagon Asset Management S.A. Xencor Inc Transaction History

Assenagon Asset Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$20.08 - $25.39 $120 - $152	-6 Reduced 0.03%	21,223 $427,000
Q1 2023 Apr 18, 2023	SELL	$25.95 - $36.95 $562,388 - $800,780	-21,672 Reduced 50.52%	21,229 $592,000
Q4 2022 Jan 12, 2023	SELL	$24.79 - $30.86 $101,291 - $126,093	-4,086 Reduced 8.7%	42,901 $1.12 Million
Q3 2022 Oct 27, 2022	SELL	$24.62 - $32.44 $2.43 Million - $3.2 Million	-98,614 Reduced 67.73%	46,987 $1.22 Million
Q1 2022 Apr 25, 2022	BUY	$26.68 - $41.63 $3.88 Million - $6.06 Million	145,601 New	145,601 $3.89 Million
Q4 2021 Feb 01, 2022	SELL	$33.67 - $43.44 $584,039 - $753,510	-17,346 Closed	0 $0
Q3 2021 Oct 19, 2021	BUY	$30.65 - $35.68 $531,654 - $618,905	17,346 New	17,346 $567,000

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.